Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high‐risk Stage II and III colon cancers? Three years' follow‐up results of the PRODIGE 22 phase II randomized multicentre trial
Colorectal Disease2021Vol. 23(6), pp. 1357–1369
Citations Over TimeTop 10% of 2021 papers
Mehdi Karoui, Claire Gallois, Guillaume Piessen, Jean-Louis Legoux, Emilie Barbier, Cécile de Chaisemartin, Cédric Lecaille, Olivier Bouché, Hanifa Ammarguellat, Francesco Brunetti, Michel Prudhomme, Jean‐Marc Régimbeau, Olivier Gléhen, Astrid Lièvre, G. Portier, Johannes Hartwig, Gaël Goujon, B. Romain, Côme Lepage, Julien Taı̈eb, for PRODIGE 22 investigators/Collaborators
Abstract
Perioperative FOLFOX has no detrimental effect on long-term oncological outcomes and may be an option for some patients with locally advanced CC.
Related Papers
- → Interstitial Lung Disease Associated with Combination Chemotherapy of Oxaliplatin, 5-Fluorouracil, and Leucovorin(2010)4 cited
- The Efficacy and Toxicity of FOLFOX Regimen（A Combination of Leucovorin and Fluorouracil with Oxaliplatin）as First-Line Treatment of Metastatic Colorectal Cancer(2009)
- → Adjuvant FOLFOX Treatment for Stage III Colorectal Cancer: Why Patients Quit FOLFOX?(2017)
- Oxaliplatin, 5-Fluorouracil, Leucovorin 복합항암화학요법 중에 발생한 간질성 폐질환 1예(2010)
- → Two Cases of Unresectable Advanced Gastric Cancer who could Resume Oral Intake following Tumor Response to Fluorouracil + folinate + oxaliplatin Therapy(2022)